ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Incyte has earned a $50 million milestone payment from Eli Lilly & Co. for the initiation of Phase III trials on baricitinib, Incyte’s oral treatment for rheumatoid arthritis. Incyte disclosed the payment a week after FDA approved Pfizer’s oral rheumatoid arthritis drug Xeljanz. Both drugs are JAK inhibitors, which target signaling pathways inside cells that play a role in the inflammation involved in arthritis. Pfizer says Xeljanz is the first JAK inhibitor for rheumatoid arthritis and the first new oral rheumatoid drug in more than 10 years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X